Coherus BioSciences (CHRS) financial statements
Coherus BioSciences reported revenue of $42M in fiscal 2025, down 15.4% a year over 9 years.
Net income was $168M and the operating margin -429.5%, against -61.2% in 2016.
The diluted share count rose 179% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Coherus BioSciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $189M | $2M | $0 | $356M | $476M | $327M | $211M | $257M | $26M | $42M |
| Cost of revenue | — | $0 | $0 | $17M | $38M | $58M | $70M | $159M | $9M | $14M |
| Gross profit | — | $2M | $0 | $339M | $438M | $269M | $141M | $98M | $18M | $28M |
| Research and development | $254M | $162M | $110M | $94M | $143M | $363M | $199M | $109M | $92M | $109M |
| Selling, general and admin | $52M | $71M | $94M | $137M | $139M | $170M | $198M | $192M | $125M | $101M |
| Operating income | -$116M | -$232M | -$204M | $108M | $156M | -$264M | -$257M | -$203M | -$200M | -$181M |
| Interest expense | $8M | $10M | $10M | $18M | $21M | $23M | $32M | $41M | $11M | $9M |
| Pre-tax income | — | -$238M | -$209M | $93M | $136M | -$287M | -$292M | -$238M | -$215M | -$183M |
| Income tax | $0 | $0 | $0 | $3M | $3M | $0 | $0 | -$380,000 | $0 | $0 |
| Net income | -$127M | -$238M | -$209M | $90M | $132M | -$287M | -$292M | -$238M | $29M | $168M |
| EPS (diluted) | -$3.04 | -$4.48 | -$3.22 | $1.23 | $1.62 | -$3.81 | -$3.76 | -$2.53 | $0.25 | $1.43 |
| Diluted shares | 42M | 53M | 65M | 73M | 83M | 75M | 78M | 94M | 115M | 117M |
| Gross margin | — | 100.0% | — | 95.2% | 92.1% | 82.4% | 66.8% | 38.2% | 66.9% | 67.2% |
| Operating margin | -61.2% | -14918.8% | — | 30.3% | 32.9% | -80.8% | -121.7% | -79.0% | -756.6% | -429.5% |
| Net margin | -67.2% | -15306.6% | — | 25.2% | 27.8% | -87.9% | -138.2% | -92.5% | 108.0% | 398.4% |
Balance sheet
Fiscal years, from Coherus BioSciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $125M | $127M | $72M | $178M | $541M | $417M | $192M | $118M | $126M | $172M |
| Receivables | $2M | — | $0 | $142M | $157M | $123M | $110M | $261M | $111M | $18M |
| Inventory | — | — | $2M | $10M | $44M | $38M | $39M | $63M | $4M | $3M |
| Total current assets | $161M | $145M | $84M | $343M | $767M | $602M | $381M | $476M | $342M | $207M |
| Property, plant and equipment | $11M | $13M | $7M | $6M | $10M | $8M | $9M | $5M | $3M | $1M |
| Goodwill | $943,000 | $943,000 | $943,000 | $943,000 | $943,000 | $943,000 | $943,000 | $943,000 | — | — |
| Total assets | $178M | $163M | $99M | $409M | $842M | $679M | $481M | $630M | $449M | $258M |
| Total current liabilities | $56M | $28M | $33M | $115M | $146M | $165M | $139M | $332M | $283M | $140M |
| Total liabilities | $159M | $132M | $138M | $304M | $561M | $582M | $618M | $823M | $581M | $197M |
| Shareholders' equity | $21M | $31M | -$39M | $105M | $281M | $98M | -$137M | -$193M | -$132M | $61M |
| Net debt | -$125M | -$127M | -$72M | -$178M | -$541M | -$417M | -$64M | -$103M | -$126M | -$89M |
Cash flow
Fiscal years, from Coherus BioSciences's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$253M | -$200M | -$159M | $28M | $154M | -$37M | -$241M | -$175M | -$20M | -$139M |
| Capital spending | $7M | $5M | $789,000 | $2M | $7M | $1M | $2M | $286,000 | — | — |
| Free cash flow | -$259M | -$205M | -$160M | $27M | $147M | -$39M | -$243M | -$175M | — | — |
| Stock-based compensation | $27M | $33M | $35M | $34M | $38M | $51M | $51M | $43M | $28M | $17M |
| Net borrowing | — | — | — | — | — | — | $159M | — | -$260M | — |
| Free cash flow margin | -136.7% | -13165.7% | — | 7.5% | 30.9% | -11.9% | -115.2% | -68.1% | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CHRS.
Open CHRS in InvestinglyQuestions
What was Coherus BioSciences's revenue in 2025?
$42M in fiscal 2025, from its 10-K filing.
From Coherus BioSciences's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.